luliconazole

(redirected from Luzu)

luliconazole

(loo-li-kon-a-zole) ,

Luzu

(trade name)

Classification

Therapeutic: antifungals
Pharmacologic: azoles
Pregnancy Category: C

Indications

Topical treatment of interdigital tinea pedis, tinea cruris and tinea corporis.

Action

Inhibits an enzyme necessary for ergosterol synthesis, required for fungal cell membranes.
Antifungal action.

Therapeutic effects

Resolution of dermal fungal infection.
Active against Trichyphyton rubrum and Epidermpophyton floccosum.

Pharmacokinetics

Absorption: Small amounts are systemically absorbed.
Distribution: Unknown.
Protein Binding: >99%
Metabolism and Excretion: Unknown.
Half-life: unk

Time/action profile (improvement/resolution of infection)

ROUTEONSETPEAKDURATION
topunk3–4 wk†unknown
†Following initiation of treatment.

Contraindications/Precautions

Contraindicated in: None noted;
Use Cautiously in: Obstetric: Use in pregnancy only if potential benefit justifies any fetal risks; Lactation: Use cautiously in breast feeding women. Pediatric: Safe and effective use in children <18 yr not established.

Adverse Reactions/Side Effects

Dermatologic

  • application site reactions

Interactions

Drug-Drug interaction

May inhibit the activity of the CYP3A4 and CYP2C19 enzymes.

Route/Dosage

Topical (Adults) Interdigital tinea pedisApply to affected and surrounding areas once daily for two weeks; Tinea cruris and tinea corporisApply to affected and surrounding areas once daily for one week.

Availability

Topical cream: 1%

Nursing implications

Nursing assessment

  • Inspect involved areas of skin and mucous membranes before and frequently during therapy. Increased skin irritation may indicate need to discontinue medication.

Potential Nursing Diagnoses

Risk for impaired skin integrity (Indications)
Risk for infection (Indications)

Implementation

  • Consult health care professional for proper cleansing technique before applying medication.
  • Topical: For Interdigital tinea pedis: Apply thin layer to cover affected area and approximately 1 inch of immediate surrounding area completely daily for 2 wk.
    • For Tinea Cruris or Tinea Corporis: Apply thin layer to affected area and approximately 1 inch of immediate surrounding area daily for 1 wk.
    • Avoid the use of occlusive wrappings or dressings unless directed by health care professional. Wash hands after application.

Patient/Family Teaching

  • Instruct patient to apply medication as directed for full course of therapy, even if feeling better. Emphasize the importance of avoiding the eyes and vagina.
  • Patients with athlete’s foot should be taught to wear well-fitting, ventilated shoes, to wash affected areas thoroughly, and to change shoes and socks at least once a day.
  • Advise patient to report increased skin irritation or lack of response to therapy to health care professional.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

  • Decrease in skin irritation and resolution of infection.
References in periodicals archive ?
Growth from launch brands, including BioTrue Multipurpose Solution, BioTrue ONEday Contact Lens, Jublia, Luzu, and Ultra Contact Lens
Doctor of Science (environmental engineering and landscape management), LUZU, 2005, Master of Science (material engineering), KTU, 1998.
08% and Luzu (luliconazole) 1% and we plan to launch ONEXTON(TM) in early 2015.